Eris Lifesciences Limited (ERIS) - Total Assets
Based on the latest financial reports, Eris Lifesciences Limited (ERIS) holds total assets worth Rs71.60 Billion INR (≈ $774.32 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ERIS capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Eris Lifesciences Limited - Total Assets Trend (2012–2025)
This chart illustrates how Eris Lifesciences Limited's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of Eris Lifesciences Limited to see how much of total assets are deployed in long-term investments.
Eris Lifesciences Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Eris Lifesciences Limited's total assets of Rs71.60 Billion consist of 17.4% current assets and 82.6% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 3.2% |
| Accounts Receivable | Rs4.59 Billion | 6.5% |
| Inventory | Rs3.35 Billion | 4.8% |
| Property, Plant & Equipment | Rs7.29 Billion | 10.4% |
| Intangible Assets | Rs37.33 Billion | 53.1% |
| Goodwill | Rs9.12 Billion | 13.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Eris Lifesciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ERIS stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eris Lifesciences Limited's current assets represent 17.4% of total assets in 2025, a decrease from 67.9% in 2012.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2025, down from 9.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 3.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 53.1% of total assets.
Eris Lifesciences Limited Competitors by Total Assets
Key competitors of Eris Lifesciences Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Eris Lifesciences Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.91 | 1.07 | 3.45 |
| Quick Ratio | 0.65 | 0.86 | 2.93 |
| Cash Ratio | 0.01 | 0.00 | 0.00 |
| Working Capital | Rs-1.32 Billion | Rs833.80 Million | Rs4.26 Billion |
Eris Lifesciences Limited - Advanced Valuation Insights
This section examines the relationship between Eris Lifesciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.23 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -0.2% |
| Total Assets | Rs70.33 Billion |
| Market Capitalization | $2.11 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Eris Lifesciences Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Eris Lifesciences Limited's assets decreased by 0.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Eris Lifesciences Limited (2012–2025)
The table below shows the annual total assets of Eris Lifesciences Limited from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs70.33 Billion ≈ $760.61 Million |
-0.22% |
| 2024-03-31 | Rs70.49 Billion ≈ $762.30 Million |
+92.21% |
| 2023-03-31 | Rs36.67 Billion ≈ $396.61 Million |
+61.40% |
| 2022-03-31 | Rs22.72 Billion ≈ $245.72 Million |
+23.84% |
| 2021-03-31 | Rs18.35 Billion ≈ $198.42 Million |
+18.20% |
| 2020-03-31 | Rs15.52 Billion ≈ $167.88 Million |
-0.09% |
| 2019-03-31 | Rs15.54 Billion ≈ $168.02 Million |
+6.41% |
| 2018-03-31 | Rs14.60 Billion ≈ $157.90 Million |
+127.78% |
| 2017-03-31 | Rs6.41 Billion ≈ $69.32 Million |
+53.14% |
| 2016-03-31 | Rs4.19 Billion ≈ $45.27 Million |
+17.16% |
| 2015-03-31 | Rs3.57 Billion ≈ $38.64 Million |
+32.03% |
| 2014-03-31 | Rs2.71 Billion ≈ $29.26 Million |
+57.50% |
| 2013-03-31 | Rs1.72 Billion ≈ $18.58 Million |
+68.35% |
| 2012-03-31 | Rs1.02 Billion ≈ $11.04 Million |
-- |
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more